Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

35.56 +9.27 (+35.26%)
Official Closing Price Updated: 4:15 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,566,593
Open 30.44
Bid (Size) 35.35 (100)
Ask (Size) 35.48 (200)
Prev. Close 26.29
Today's Range 30.10 - 36.28
52wk Range 13.79 - 36.28
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Immunovant Stock Surges Despite Disappointing Earnings Miss ↗
Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss. 
Via Benzinga

Performance

YTD
+37.2%
+37.2%
1 Month
+24.6%
+24.6%
3 Month
+33.4%
+33.4%
6 Month
+53.5%
+53.5%
1 Year
+137.1%
+137.1%

More News

Read More
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
Immunovant Inc (NASDAQ:IMVT) Surges 26% Pre-Market on Strong IMVT-1402 Clinical Data Despite Wider Q4 Loss ↗
Via Chartmill
Immunovant Inc (NASDAQ:IMVT) Reports Q3 FY2026 Results, Beats EPS Estimates and Provides Key Clinical Updates ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Immunovant Q4 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
Via MarketMinute
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
Via MarketMinute
Topics Intellectual Property
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
Via The Motley Fool
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Via Finterra
Topics Economy
News headline image
Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish ↗
Via The Motley Fool
News headline image
Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares ↗
Via The Motley Fool
Topics Government
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Immunovant (IMVT) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates ↗
Via Chartmill
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?
Yes, Immunovant, Inc. - Common Stock is publicly traded.
What exchange does Immunovant, Inc. - Common Stock trade on?
Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immunovant, Inc. - Common Stock?
The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market
What is the current price of Immunovant, Inc. - Common Stock?
The current price of Immunovant, Inc. - Common Stock is 35.56
When was Immunovant, Inc. - Common Stock last traded?
The last trade of Immunovant, Inc. - Common Stock was at 05/20/26 04:15 PM ET
What is the market capitalization of Immunovant, Inc. - Common Stock?
The market capitalization of Immunovant, Inc. - Common Stock is 4.09B
How many shares of Immunovant, Inc. - Common Stock are outstanding?
Immunovant, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.